- Price
- $0.71
- Day
- +3.32%
- Mkt Cap
- $119.65M
- 52W Range
- $0.55 – $2.76
- Volume
- 2.89M
- Beta
- 2.52
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.63, signifying a -6.44% move from its prior day's close.
Read full article
– Phase 2a study of CTEV in coronary artery bypass grafting (CABG) is expected to start this quarter – – Progression of CTEV into human study supported by positive preclinical results presented at multiple scientific meetings and in a recent publication – DURHAM, N.C., July 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced that the Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for a first-in-human clinical study of the coronary tissue engineered vessel (CTEV) in coronary artery bypass grafting (CABG).
Read full article
In the latest trading session, Humacyte, Inc. (HUMA) closed at $0.67, marking a +2.22% move from the previous day.
Read full article
Humacyte, Inc. (HUMA) closed at $0.66 in the latest trading session, marking a -1.28% move from the prior day.
Read full article